Table 1 Patient characteristics
All patients (n = 125) | 1976–2006 cohort (n = 62) | 2007–2014 cohort (n = 63) | p-Value* | ||
|---|---|---|---|---|---|
Age at diagnosis (years) | Median (IQR) | 34 (28.0–41.5) | 34 (28.3–38.8) | 35 (28.0–41.0) | 0.16 |
Antecedent pregnancy | Live birth | 81 (64.8%) | 37 (59.7%) | 44 (69.8%) | 0.23 |
CHM | 19 (15.2%) | 8 (12.9%) | 11 (18.0%) | ||
PHM | 1 (0.8%) | 1 (1.6%) | 0 (0.0%) | ||
Abortion | 9 (7.2%) | 6 (9.7%) | 3 (4.8%) | ||
Miscarriage | 14 (11.2%) | 10 (16.1%) | 4 (6.3%) | ||
Time since antecedent pregnancy (months) | Median (IQR) | 16 (10.5–45.5) | 16 (12.0–39.3) | 16 (10.0–48.0) | 0.39 |
<48 months | 95 (76.0%) | 49 (79.0%) | 46 (73.0%) | ||
≥ 48 months | 30 (24.0%) | 13 (21.0%) | 17 (27.0%) | 0.43 | |
FIGO stage | I | 74 (59.2%) | 34 (54.8%) | 40 (63.5%) | 0.70 |
II | 10 (8.0%) | 5 (8.1%) | 5 (7.9%) | ||
III | 27 (21.6%) | 16 (25.8%) | 11 (17.5%) | ||
IV | 14 (11.2%) | 7 (11.3) | 7 (11.1%) | ||
Baseline serum hCG | 1 to ≤4 | 22 (17.6%) | 3 (4.8%) | 19 (30.1%) | 0.14 |
>4 to ≤100 | 37 (29.6%) | 20 (32.3%) | 17 (27.0%) | ||
>100 to ≤1000 | 32 (25.6%) | 21 (33.9%) | 11 (17.5%) | ||
>1000 to ≤10,000 | 15 (12.0%) | 9 (14.5%) | 6 (9.5%) | ||
>10,000 | 19 (15.2%) | 9 (14.5%) | 10 (15.9%) | ||
Myometrial invasion | Inner half | 23 (18.4%) | 9 (14.5%) | 14 (22.2%) | 0.43 |
Outer half | 50 (40.0%) | 28 (45.2%) | 22 (34.9%) | ||
Serosal invasion | 15 (12.0%) | 7 (11.3%) | 8 (12.7%) | ||
Unknown | 37 (29.6%) | 18 (29.0%) | 19 (30.2%) | ||
Lympho-vascular invasion | Absent | 44 (35.2%) | 15 (24.2%) | 29 (46.1%) | 0.01 |
Present | 49 (39.2%) | 29 (46.8%) | 20 (31.7%) | ||
Unknown | 32 (25.6%) | 18 (29.0%) | 14 (22.2%) | ||
Mitotic count | Median (IQR) | 3.0 (1.7–8.0) | 4.0 (2.5–7.6) | 2.5 (1.0–8.5) | 0.09 |
